Background
IC50: 16 nM
CC-223 is an orally bioavailable mTOR inhibitor.
The mammalian target of rapamycin (mTOR) pathway is critical for tumor development, and mTOR inhibitors have revealed modest results.
In vitro: CC-223 was identified as an ATP–competitive inhibitor of the mTOR kinase targeting mTORC1 of both 4EBP1 and p70 S6 kinase 1 and mTORC2, which prevented the upregulation of AKT phosphorylation. Moreover, CC-223 was selectively potent to mTOR kinase while showed more than 150-fold sensitivity against the related lipid kinase, PI3Ka. In addition, CC-223 was active over many non-Hodgkin lymphoma cell lines and solid tumor lines such as including glioma, breast, hepatocellular carcinoma, as well as non–small cell lung cancer [1].
In vivo: In animal study, CC-223 was selected for evaluation in PC-3 tumor bearing efficacy mouse models. Mice were orally treated with vehicle or various doses of CC-223 once daily or twice daily at a dose of 5 mL/kg for 21 days, and the final reductions of tumor volume were measured following the final day of dosing. Results showed that All CC-223 had dose- and schedule-dependent inhibition of tumor growth in the PC-3 model. Moreover, the maximum observed efficacy for CC-223 was determined to be 87%, at its tolerated dose of 25 mg/kg q.d. [1].
Clinical trial: In previous clinical study, CC-223 was found to be tolerable with manageable toxicities. In addition, the preliminary antitumor activity, such as tumor regression and evidence of mTORC1/mTORC2 pathway inhibition were also observed [2].
参考文献:
[1] Mortensen DS, et al.? Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223. J Med Chem. 2015 Jul 9;58(13):5323-5333.
[2] Bendell JC, et al.? A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1;121(19):3481-90.
Protocol
Kinase experiment: | Counter screen against 246 protein kinases is outsourced and completed at a fixed CC-223 concentration (10 μM). Follow-up IC50 value determinations for ephrin type-B receptor 3 kinase (EPHB3), colony stimulating factor 1 receptor tyrosine kinase (CSF1R or cFMS), and FMS-related tyrosine kinase 4 (FLT4) are outsourced to Invitrogen[1]. |
Cell experiment: | For other cell panel proliferation assays, CC-223 (1 nM, 100 nM and 1 μM) is spotted via an acoustic dispenser (EDC ATS-100) into an empty 384-well plate. Cells are diluted to desired densities and added directly to the compound-spotted plates. Cells are allowed to grow for 72 hours. Viability is assessed via Cell Titer-Glo. All data are normalized and represented as a percentage of the DMSO-treated cells. Results are then expressed as GI50 and/or IC50 values[1]. |
Animal experiment: | Mice[1]Female 6- to 8-weeks-old CB17 SCID mice are inoculated s.c. with 2×106 PC-3 cells. When tumors reach approximately 125 mm3, mice are randomized and treated once daily, twice daily, or every 2 days orally with vehicle or various doses of CC-223, at a dose volume of 5 mL/kg. The twice-daily doses are administered with a 10 hours separation between the morning and evening doses. Tumor volumes are determined before the initiation of treatment and are considered as the starting volumes. Tumors are measured twice a week for the duration of the study. The long and short axes of each tumor are measured using a digital caliper in millimeters. The tumor volumes are calculated. The tumor volumes are expressed in cubic millimeters (mm3). |
参考文献: [1]. Mortensen DS, et al. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305. |
没有评价数据